![Thumbnail_Screen Shot 2022-04-26 at 15.19.02[1]u Disease proteins (target) are attached to a degradation tag (tag). Upon treatment with a tag-binding PROTAC drug, the target is signalled for removal by recruitment of the E3 complex that attaches the degrader signal ubiquitin (Ub).](https://i0.wp.com/innovationtoronto.com/wp-content/uploads/2022/05/Thumbnail_Screen-Shot-2022-04-26-at-15.19.021u.png?fit=300%2C297&ssl=1)
Disease proteins (target) are attached to a degradation tag (tag). Upon treatment with a tag-binding PROTAC drug, the target is signalled for removal by recruitment of the E3 complex that attaches the degrader signal ubiquitin (Ub).
Researchers have boosted pioneering technology to show whether potential treatments are worth progressing into human trials, in a game-changing move that could dramatically reduce the high failure rates in drug discovery and development.
The WEHI-led team is using protein degrader technology to test the efficacy and safety of drugs by better mimicking clinical settings, with a collaborative Australian project already using the system to establish promising drug targets for a range of hard-to-treat cancers.
At a glance
- Pioneering technology can assess how effective and safe a drug target could be for patients, far earlier in the research process.
- A collaborative effort is currently leveraging the technology to validate drug targets for a range of cancers.
- The protein degrader technology offers a revolutionary approach for substantially reducing the pharmaceutical industry’s high drug development failure rate.
Almost 95% of biomedical projects fail before entering human clinical trials with the average cost of bringing a new drug to market estimated to be around US$1.8billion. A key issue is the difficulty of assessing a drug’s true safety and effectiveness in preclinical studies.
While conventional drug development aims to inhibit the activity of disease-causing proteins, protein degrader technology looks to completely destroy those proteins, with precision targeting.
The technology enables scientists to deliver far more relevant results from pre-clinical testing, to potentially bring safe and effective new treatments to patients faster.
In a new study published in Nature Communications, WEHI researchers Dr Charlene Magtoto, Dr Rebecca Feltham and Dr Christoph Grohmann (now at Nurix Therapeutics) have significantly extended our understanding of one type of protein degrader technology by expanding on current validation strategies, which could boost the number of drugs successfully entering human trials.
A collaboration between WEHI and multiple institutes across Australia is already capitalising on the revolutionary technology to validate a range of previously ‘undruggable’ proteins and help develop new therapies to treat cancers.
Reimagining drug discovery
About 80% of disease-causing proteins currently cannot be targeted by conventional drugs.
Targeted protein degraders (TPDs), commonly known as Proteolysis targeting chimera (PROTAC), is a pioneering technology that can hit these previously invincible targets.
While current drugs and technology only inhibit the specific activity of a protein, TPDs work by triggering the destruction of the proteins that cause the disease itself.
TPD has the potential to deliver precision treatments by only targeting disease-causing proteins, leaving healthy parts of the body untouched.
The WEHI-led team focused on developing a tag system to help researchers overcome a significant hurdle in the drug development process.
Dr Charlene Magtoto said this system enables scientists to use drugs that interact with a tag, opening up virtually the entire proteome for target validation.
“Finding a drug to bind onto the protein itself can be difficult and often a reason why researchers reach a crossroads in drug development,” Dr Magtoto said.
“Attaching a small generic tag onto any protein of interest to enable a destroyer protein to remove it allows us to wipe out any protein just by targeting the tag.
“This is a game-changer technology that will ensure only the best targets enter into drug discovery pipelines.”
Dr Christoph Grohmann said a partnership with Promega was crucial to developing the new tagging system, collaborating with scientists at the global biotech company and using their NanoLuc® luciferase technology.
“WEHI is an emerging leader in TPD technology, and this significant collaboration enabled our team to leverage industrial drug discovery expertise and academic medical research to enhance the technology at a much faster pace,” Dr Grohmann said.
Crucial cancer targets
The lack of effective new drugs is a particular barrier for cancer researchers, with as few as 1 in 15 developmental drugs progressing into the clinic.
WEHI researchers are working with other institutions across the country to develop TPDs for cancer treatment as part of a current project funded by the Australian Medical Research Future Fund (MRFF).
Dr Rebecca Feltham, who leads the MRFF tag-degrader program, said the collaboration was helping researchers quickly identify whether their cancer targets were worth pursuing.
“Most of the 150,000 Australians diagnosed with cancer each year are still treated with drugs that came onto the market over 25 years ago, which can cause significant side-effects,” she said.
“As this pioneering technology enables us to better identify genuine targets early in the research process, we could radically accelerate the development of lifesaving new treatments for cancer and other diseases.”
Dr Feltham has used the tag-targeting TPD technology to investigate 24 potential drug targets – 19 of which link to cancer.
Unlike other systems currently used in the field, the protein degradation triggered by tag-targeting TPD technology is reversible. Once the drug is removed, the protein comes back.
“This is exactly what happens in clinical settings and this technology allows us to mimic real TPD treatment scenarios early on in the development process, far better than any technology we have available today,” Dr Feltham said.
Researchers hope their findings will trigger a broader awareness to the benefits of TPD technology to help reduce the burden of cost currently presented by high drug failure rates.
Original Article: Research boosts ‘game-changing’ technology to strengthen drug development
More from: Walter and Eliza Hall Institute | University of Dundee
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Reducing drug discovery failure rates
- Promega Developments in the Biotech Space Significantly Accelerate the Discovery Process
Promega Developments in the Biotech Space Significantly Accelerate the Discovery Process Promega, a leading manufacturer of products for the life sciences industry, has developed CRISPR-generated ...
- Drug Discovery Services Market: Future Growing Trends and Forecast from 2023 to 2030
Drug Discovery Services is a range of services that suppliers help companies reduce costs and save time ... the report reveals production rates, costing, overall pricing, revenue generation ...
- Drug discovery on an unprecedented scale
By combining our ideas, resources and technology, it was possible to reach our ambitious goals," continues Professor Antti Poso, who leads the computational drug discovery group within the ...
- 3 things to understand how AI might help develop new, cost-effective drug treatments
Researchers have estimated that AI-powered drug discovery could drive as much as ... I’m excited for anything that promises to reduce the time and cost of getting new drugs to market and ...
- New Malaria Treatment Strategies May Reduce Failures by 81%
Artemisinin-based combination therapies (ACTs) are globally accepted first-line treatments for malaria, but resistance to ACTs has emerged in recent years. Scientists have now found that ...
Go deeper with Google Headlines on:
Reducing drug discovery failure rates
[google_news title=”” keyword=”reducing drug discovery failure rates” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
Speeding up drug discovery
- Chinese AI-developed drug offers hope to sufferers of obesity and diabetes
Developed using artificial intelligence, the weight-loss and diabetes drug MDR-001 is currently in its phase 2 clinical trials The use of AI in drug discovery is helping to keep costs down and speed ...
- Drug Discovery on an Unprecedented Scale
Boosting virtual screening with machine learning allowed for a 10-fold time reduction in the processing of 1.56 billion drug-like molecules. Researchers from the University of Eastern Finland teamed ...
- SRI International spins out Synfini, an AI-powered drug discovery platform provider
Silicon Valley-based nonprofit scientific research institute SRI International said today it’s spinning out its patented Synfini drug discovery platform as an independent startup named Synfini Inc.
- Drug discovery on an unprecedented scale
Boosting virtual screening with machine learning allowed for a 10-fold time reduction in the processing of 1.56 billion drug-like molecules ... learning in the speed-up of giga-scale virtual ...
- Machine Learning Accelerates Drug Discovery
In a groundbreaking research endeavor, scientists from the University of Eastern Finland have unlocked a new era in drug discovery, capitalizing on the potential of machine learning. Through a ...
Go deeper with Google Headlines on:
Speeding up drug discovery
[google_news title=”” keyword=”speeding up drug discovery” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]